RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM) from its SEC filings: 2025 revenue $189.8 million (+46% vs the year before), net margin -0%, free cash flow -$116.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $189.8 million |
| Revenue growth | +46% |
| Net income | -$196,539 |
| Net margin | -0.1% |
| Free cash flow | -$116.6 million |
| Diluted EPS | $-3.11 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +47% |
| Cash | $65.6 million |
| Long-term debt | $93.4 million |
| Share count, 1 year | +4% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.